COVID-19: New study examines monoclonal antibodies - Medical ...
Companies, agencies, institutions, etc
the Centers for Disease Control and Prevention
CDC
COPD
COVID-19
Medical News
Molecular Microbiology & Immunology
Johns Hopkins Bloomberg School of Public Health
the Food and Drug Administration
FDA
the University of Pittsburgh Medical Center (UPMC
the University of Pittsburgh School of Medicine
the Infectious Disease Society of America
the United States Department of Health and Human Services
EUA
MNT
Pitt’s Division of Infectious Diseases
the UPMC Community Hospital Antimicrobial Stewardship Efforts
CHASE)
People
Arturo Casadevall
Ryan Bariola
Sinopharm
Groups
COVID-19
Physical locations
No matching tags
Places
No matching tags
Locations
the United States
Baltimore
MD
a]s
Events
No matching tags
Summary
Treatment of COVID-19 using monoclonal antibodies may be an effective option for people at risk of severe illness.The body produces antibodies to help it fight infections. This study examined the use of bamlanivimab monoclonal antibody therapy and its effectiveness in reducing death and hospitalization in high-risk people with COVID-19. The scientists followed the participants for 28 days.Dr. Casadevall told MNT in regards to this study that “the results with bamlanivimab monoclonal antibody treatment in patients with COVID-19 show reduced hospital admissions and mortality with early use, highlighting the potential of antibody-based therapies in fighting this disease.” The study results showed decreased hospitalization and mortality among those who received bamlanivimab than those who did not.
As said here by https://www.medicalnewstoday.com/articles/covid-19-more-evidence-that-monoclonal-antibodies-reduce-risk-of-death